A.R.T. Advisors’s Krystal Biotech KRYS Stock Holding History

A.R.T. Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,122	Closed	-$351K	–	1535
2019 Q3	$351K	Buy	+10,122	New	+$452K	0.02%	995

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

A.R.T. Advisors's KRYS Position: Q4 2019 in Review

A.R.T. Advisors sold out of Krystal Biotech (KRYS) in Q4 2019, closing a stake of 10,122 shares — an estimated $351K sold.

A.R.T. Advisors first reported a position in KRYS in Q3 2019 and held it in 1 quarter. The position peaked at $351K in Q3 2019. 90 funds tracked by Wall St. Rank hold KRYS as of Q4 2019.

A.R.T. Advisors reported no remaining Krystal Biotech position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 10,122 Krystal Biotech shares in Q4 2019, an estimated $351K.
A.R.T. Advisors first reported a position in Krystal Biotech in Q3 2019 and held it in 1 quarter.
A.R.T. Advisors's Krystal Biotech position peaked at $351K in Q3 2019.
90 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.